Diagnostica Stago Displays STA Compact Max and STA Satellite Max Analyzers at MEDLAB
|
By LabMedica International staff writers Posted on 06 Feb 2020 |

Illustration
Diagnostica Stago (Asnières-sur-Seine, France) exhibited its STA Compact Max and STA Satellite Max analyzers at MEDLAB Middle East, which took place from 3-6 February 2020 at the Dubai World Trade Centre. MEDLAB Middle East, the Middle East & North Africa (MENA) region’s largest medical laboratory exhibition and congress, drew over 25,800 medical laboratory industry professionals and 600 exhibitors from 35 countries.
At this year’s MEDLAB, Diagnostica Stago displayed STA Compact Max, a fully automated benchtop hemostasis analyzer with an expansive test menu and enhanced throughput, making it the perfect system offering for mid-sized laboratories. The system’s unique method of sample management offers moderate throughput and rapid processing of STAT samples with no impact to the instrument’s time to result. With 96 sample positions and 45 reagent positions, the Compact Max can easily handle the workload with minimal intervention from the operator. Integrated STA Coag Expert Software provides full auto-verification, repeat/reflex testing, a comprehensive QC package, accreditation tools, automated maintenance logs, TAT monitoring and maintains five years of patient archives onboard. The Compact Max is available with an optional cap-piercing system to reduce bio-hazard exposure risks.
Alongside the STA Compact Max, Diagnostica Stago exhibited STA Satellite Max, a hemostasis analyzer designed specifically for “satellite” labs looking for a device that meets their needs while guaranteeing results as reliable as those obtained in large specialized laboratories. The STA Satellite Max includes a comprehensive test menu, designed for the needs of today’s low-volume laboratory, offering all routine and STAT tests. Connected to the STA Coag Expert, the STA Satellite Max automatically runs result validation operations and can link “satellite” labs within a group to benefit from additional connected solutions, including My Expert QC.
Related Links:
Diagnostica Stago
At this year’s MEDLAB, Diagnostica Stago displayed STA Compact Max, a fully automated benchtop hemostasis analyzer with an expansive test menu and enhanced throughput, making it the perfect system offering for mid-sized laboratories. The system’s unique method of sample management offers moderate throughput and rapid processing of STAT samples with no impact to the instrument’s time to result. With 96 sample positions and 45 reagent positions, the Compact Max can easily handle the workload with minimal intervention from the operator. Integrated STA Coag Expert Software provides full auto-verification, repeat/reflex testing, a comprehensive QC package, accreditation tools, automated maintenance logs, TAT monitoring and maintains five years of patient archives onboard. The Compact Max is available with an optional cap-piercing system to reduce bio-hazard exposure risks.
Alongside the STA Compact Max, Diagnostica Stago exhibited STA Satellite Max, a hemostasis analyzer designed specifically for “satellite” labs looking for a device that meets their needs while guaranteeing results as reliable as those obtained in large specialized laboratories. The STA Satellite Max includes a comprehensive test menu, designed for the needs of today’s low-volume laboratory, offering all routine and STAT tests. Connected to the STA Coag Expert, the STA Satellite Max automatically runs result validation operations and can link “satellite” labs within a group to benefit from additional connected solutions, including My Expert QC.
Related Links:
Diagnostica Stago
Latest MEDLAB 2020 News
- DAS Srl Exhibits Range of Fully Automated Systems at MEDLAB Middle East 2020
- GeneMatrix Promotes Sex and Respiratory Infection Testing Products at MEDLAB
- Mindray Showcases Comprehensive IVD Solutions Portfolio at MEDLAB Middle East 2020
- New Technology that Detects MRSA in 15 Minutes Introduced at MEDLAB Middle East 2020
- Vircell Exhibits Its New VirClia Lotus and qSPEED-OLIGO Systems at MEDLAB
- Randox Showcases New All-In-One Solution for Molecular Diagnostics at MEDLAB Middle East 2020
- EKF Diagnostics Displays POC Analyzers for Hemoglobin, HbA1c And Lactate at MEDLAB Middle East
- Erba Mannheim Launches New Electrolyte Analyzer with Maintenance-free Electrodes at MEDLAB 2020
- MEDLAB Middle East 2020 Addresses Future of Laboratory Medicine
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








